Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
72 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Gamma Secretase (EC 3.4.23.46) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Gamma Secretase (EC 3.4.23.46) - Pipeline Review, H1 2016', provides in depth analysis on Gamma Secretase (EC 3.4.23.46) targeted pipeline therapeutics. The report provides comprehensive information on the Gamma Secretase (EC 3.4.23.46), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Gamma Secretase (EC 3.4.23.46) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.46) - The report reviews Gamma Secretase (EC 3.4.23.46) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Gamma Secretase (EC 3.4.23.46) targeted therapeutics and enlists all their major and minor projects - The report assesses Gamma Secretase (EC 3.4.23.46) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Gamma Secretase (EC 3.4.23.46) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Gamma Secretase (EC 3.4.23.46) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Gamma Secretase (EC 3.4.23.46) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Gamma Secretase (EC 3.4.23.46) Overview 8 Therapeutics Development 9 Gamma Secretase (EC 3.4.23.46) - Products under Development by Stage of Development 9 Gamma Secretase (EC 3.4.23.46) - Products under Development by Therapy Area 10 Gamma Secretase (EC 3.4.23.46) - Products under Development by Indication 11 Gamma Secretase (EC 3.4.23.46) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Gamma Secretase (EC 3.4.23.46) - Products under Development by Companies 14 Gamma Secretase (EC 3.4.23.46) - Products under Development by Universities/Institutes 16 Gamma Secretase (EC 3.4.23.46) - Therapeutics Assessment 18 Assessment by Monotherapy/Combination Products 18 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 22 Gamma Secretase (EC 3.4.23.46) - Companies Involved in Therapeutics Development 23 Amgen Inc. 23 Astellas Pharma Inc. 24 Bristol-Myers Squibb Company 25 Critical Outcome Technologies Inc. 26 FORUM Pharmaceuticals Inc. 27 Humanetics Corporation 28 Lipopharma Therapeutics SL 29 Merck & Co., Inc. 30 NeuroGenetic Pharmaceuticals, Inc. 31 Pfizer Inc. 32 Stemline Therapeutics, Inc. 33 Sumitomo Dainippon Pharma Co., Ltd. 34 Takeda Pharmaceutical Company Limited 35 Gamma Secretase (EC 3.4.23.46) - Drug Profiles 36 AS-2715348 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 BMS-869780 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 BMS-986115 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 GSI-34 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 LP-226A1 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 MK-0752 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 MRK-003 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 NGP-328 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 NGP-555 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 NIC-515 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 nirogacestat - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 SL-301 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 SL-302 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Small Molecule 2 to Inhibit Gamma Secretase for Alzheimer's Disease - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 Small Molecule Bi-functional Beta Secretase and Gamma Secretase Inhibitors for Alzheimer Disease - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Small Molecules to Inhibit Ap1B Gamma-Secretase for Alzheimer's Disease - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Small Molecules to Inhibit Gamma Secretase for Hearing Loss - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Small Molecules to Inhibit Gamma Secretase for Sensorineural Hearing Loss - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 Small Molecules to Modulate Gamma Secretase for Alzheimer's Disease - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Small Molecules to Modulate Gamma Secretase for Alzheimer's Disease - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 Gamma Secretase (EC 3.4.23.46) - Dormant Projects 64 Gamma Secretase (EC 3.4.23.46) - Discontinued Products 66 Gamma Secretase (EC 3.4.23.46) - Featured News & Press Releases 67 Nov 10, 2015: NeuroGenetic Pharmaceuticals Awarded $2.5 Million Grant From NIA to Conduct Clinical Trials with NGP 555 to Treat and Prevent Alzheimer's Disease; Reports Initial Results of Phase 1a Clinical Trial 67 Sep 29, 2014: FDA Approves NeuroGenetic Pharmaceuticals Application to Begin Clinical Trials for Its NGP 555 Compound to Treat and Prevent Alzheimer's Disease 67 Jun 27, 2012: Humanetics Announces Alzheimer's Disease Patent Issuance 67 Jul 15, 2011: NeuroGenetic Pharma Receives SBIR Grant For Preclinical Development And IND Application Of NGP 555 To Treat Alzheimer's Disease 68 Jul 21, 2009: Critical Outcome Technologies Inc. Announces The Launch Of A Drug Discovery Program For Alzheimer'S Disease 68 Jul 12, 2009: Humanetics' Development Partner Mount Sinai Presents Phase IIA Preliminary Clinical Findings Of NIC5-15 At the Alzheimer's Association 2009 69 Mar 30, 2006: Humanetics Corporation Announces FDA Approval Of Investigational New Drug (IND) Application For NIC5-15. 69 Dec 01, 2005: Humanetics Signs Exclusive License With Mount Sinai School Of Medicine To Develop Oral Agent NIC5-15, To Combat Alzheimer's Disease 70 Appendix 71 Methodology 71 Coverage 71 Secondary Research 71 Primary Research 71 Expert Panel Validation 71 Contact Us 71 Disclaimer 72
List of Tables
Number of Products under Development for, H1 2016 9 Number of Products under Development by Therapy Area, H1 2016 10 Number of Products under Development by Indication, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Early Stage Products, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Products under Development by Companies, H1 2016 15 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Assessment by Monotherapy/Combination Products, H1 2016 18 Number of Products by Stage and Mechanism of Action, H1 2016 20 Number of Products by Stage and Route of Administration, H1 2016 21 Number of Products by Stage and Molecule Type, H1 2016 22 Pipeline by Amgen Inc., H1 2016 23 Pipeline by Astellas Pharma Inc., H1 2016 24 Pipeline by Bristol-Myers Squibb Company, H1 2016 25 Pipeline by Critical Outcome Technologies Inc., H1 2016 26 Pipeline by FORUM Pharmaceuticals Inc., H1 2016 27 Pipeline by Humanetics Corporation, H1 2016 28 Pipeline by Lipopharma Therapeutics SL, H1 2016 29 Pipeline by Merck & Co., Inc., H1 2016 30 Pipeline by NeuroGenetic Pharmaceuticals, Inc., H1 2016 31 Pipeline by Pfizer Inc., H1 2016 32 Pipeline by Stemline Therapeutics, Inc., H1 2016 33 Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 34 Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 35 Dormant Projects, H1 2016 64 Dormant Projects (Contd..1), H1 2016 65 Discontinued Products, H1 2016 66
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
